Generation Bio Q2 EPS $(0.55) Up From $(1.50) YoY

Generation Bio (NASDAQ:GBIO) reported quarterly losses of $(0.55) per share. This is a 63.33 percent increase over losses of $(1.50) per share from the same period last year.

byBenzinga Newsdesk

August 11, 2021

1 minute read

Generation Bio (NASDAQ:GBIO) reported quarterly losses of $(0.55) per share. This is a 63.33 percent increase over losses of $(1.50) per share from the same period last year.

Duluth’s Q4 Earnings Top Estimates; Clocks 3.7% Decline In Women’s Apparel Sales

By Shivani Kumaresan

March 10, 2:27 PM

Duluth Holdings Inc (NASDAQ:DLTH) reported fourth-quarter FY21 sales growth of 5.8% year-on-year, to $270.76 million, beating the consensus of $268.45 million.…

DLTH

B. Riley Securities Initiates Coverage On Lument Finance Trust with Buy Rating, Announces Price Target of $4.5

By Benzinga Newsdesk

October 15, 11:54 AM

B. Riley Securities analyst Matt Howlett initiates coverage on Lument Finance Trust (NYSE:LFT) with a Buy rating and announces Price Target of $4.5.

LFT

Brickell Biotech Q2 EPS $(0.16) Misses $(0.12) Estimate, Sales $151.00K Down From $607.00K YoY

By Benzinga Newsdesk

August 12, 4:37 PM

Brickell Biotech (NASDAQ:BBI) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 62.79 percent increase over losses of $(0.43) per share from

BBI

Inotiv Sees FY23 Revenue Of At Least $580M Vs $576.72M Est.; $75M Of Adjusted EBITDA

By Happy Mohamed

February 14, 1:38 AM

Reiterating Select Financial Guidance for the Full Fiscal Year Ending September 30, 2023 ("FY 2023") The Company's guidance takes into account a number of factors, including existing

NOTV

Generation Bio Q2 EPS $(0.55) Up From $(1.50) YoY

Related Posts

Duluth’s Q4 Earnings Top Estimates; Clocks 3.7% Decline In Women’s Apparel Sales

B. Riley Securities Initiates Coverage On Lument Finance Trust with Buy Rating, Announces Price Target of $4.5

Brickell Biotech Q2 EPS $(0.16) Misses $(0.12) Estimate, Sales $151.00K Down From $607.00K YoY

Inotiv Sees FY23 Revenue Of At Least $580M Vs $576.72M Est.; $75M Of Adjusted EBITDA